CA2904797A1 - Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer - Google Patents

Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer Download PDF

Info

Publication number
CA2904797A1
CA2904797A1 CA2904797A CA2904797A CA2904797A1 CA 2904797 A1 CA2904797 A1 CA 2904797A1 CA 2904797 A CA2904797 A CA 2904797A CA 2904797 A CA2904797 A CA 2904797A CA 2904797 A1 CA2904797 A1 CA 2904797A1
Authority
CA
Canada
Prior art keywords
egfr
inhibitor
compound
dacomitinib
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2904797A
Other languages
English (en)
French (fr)
Inventor
Zelanna Iris GOLDBERG
John Charles Kath
Stephen Paul Letrent
Scott Lawrence Weinrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA2904797A1 publication Critical patent/CA2904797A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2904797A 2013-03-14 2014-03-03 Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer Abandoned CA2904797A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786130P 2013-03-14 2013-03-14
US61/786,130 2013-03-14
PCT/IB2014/059401 WO2014140989A2 (en) 2013-03-14 2014-03-03 Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
CA2904797A1 true CA2904797A1 (en) 2014-09-18

Family

ID=50288209

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2904797A Abandoned CA2904797A1 (en) 2013-03-14 2014-03-03 Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer

Country Status (14)

Country Link
EP (1) EP2968336A2 (zh)
JP (1) JP2014177456A (zh)
KR (1) KR20150119210A (zh)
CN (1) CN105073116A (zh)
AR (1) AR095197A1 (zh)
AU (1) AU2014229468A1 (zh)
BR (1) BR112015023020A2 (zh)
CA (1) CA2904797A1 (zh)
IL (1) IL240730A0 (zh)
MX (1) MX2015012106A (zh)
RU (1) RU2015137596A (zh)
SG (1) SG11201506531WA (zh)
TW (1) TW201446248A (zh)
WO (1) WO2014140989A2 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110259C2 (uk) 2011-09-22 2015-12-10 Пфайзер Інк. Похідні піролопіримідину і пурину
CN104311573B (zh) * 2013-09-18 2017-12-15 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
WO2016051380A1 (en) * 2014-10-01 2016-04-07 Sun Pharmaceutical Industries Limited Crystalline form of afatinib dimaleate
EP3226869A4 (en) * 2014-12-03 2018-07-18 Auckland UniServices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
WO2017027567A1 (en) * 2015-08-11 2017-02-16 Principia Biopharma, Inc. Processes for preparing an fgfr inhibitor
WO2017164887A1 (en) * 2016-03-25 2017-09-28 OSI Pharmaceuticals, LLC Pulse dosing regimen and methods for treatment
US10583142B2 (en) 2016-03-25 2020-03-10 OSI Pharmaceuticals, LLC Pulse dosing regimen and methods of treatment
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
WO2017200016A1 (ja) * 2016-05-17 2017-11-23 公益財団法人がん研究会 Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬
US20190125751A1 (en) * 2016-05-18 2019-05-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
WO2018165145A1 (en) * 2017-03-08 2018-09-13 Ariad Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine
EA202091372A1 (ru) 2017-12-05 2020-10-05 Оскотек Инк. Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2
WO2024026056A2 (en) * 2022-07-29 2024-02-01 Accutar Biotechnology, Inc. Heteroaryl compounds as egfr inhibitors and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102146059A (zh) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 喹唑啉衍生物、制备方法及其应用
UA110259C2 (uk) * 2011-09-22 2015-12-10 Пфайзер Інк. Похідні піролопіримідину і пурину

Also Published As

Publication number Publication date
TW201446248A (zh) 2014-12-16
IL240730A0 (en) 2015-10-29
WO2014140989A2 (en) 2014-09-18
SG11201506531WA (en) 2015-09-29
AR095197A1 (es) 2015-09-30
KR20150119210A (ko) 2015-10-23
WO2014140989A3 (en) 2014-12-04
BR112015023020A2 (pt) 2017-07-18
EP2968336A2 (en) 2016-01-20
CN105073116A (zh) 2015-11-18
JP2014177456A (ja) 2014-09-25
MX2015012106A (es) 2016-01-12
AU2014229468A1 (en) 2015-09-03
RU2015137596A (ru) 2017-04-17

Similar Documents

Publication Publication Date Title
CA2904797A1 (en) Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer
JP6862495B2 (ja) Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置
JP6667573B2 (ja) 新規なアミノピリミジン誘導体
KR102236605B1 (ko) 피리도피리미딘온 cdk2/4/6 억제제
US10766903B2 (en) Piperidine derivatives as inhibitors of ubiquitin specific protease 7
US10258603B2 (en) Therapeutic compounds and uses thereof
JP6387360B2 (ja) 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
US8865894B2 (en) Oxazolidin-2-one compounds and uses thereof
TWI603977B (zh) 作為激酶抑制劑之化合物及組合物
US10968203B2 (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders
EP3455219A1 (en) Amine-linked c3-glutarimide degronimers for target protein degradation
KR20200108298A (ko) 벤즈아미드 화합물
KR20180097530A (ko) 단백질분해 표적화 키메라 화합물(Proteolysis Targeting Chimera compound) 및 그의 제조 및 사용 방법
JP6262245B2 (ja) オキサゾリジン−２−オンピリミジン誘導体
US20130096149A1 (en) Heteroaryl compounds and compositions as protein kinase inhibitors
US12071425B2 (en) Phenoxy-pyridyl-pyrimidine compounds and methods of use
BR112020013247A2 (pt) amidas heterocíclicas como inibidores de quinase
JP2023502662A (ja) Ａｌｋ５阻害剤としての置換１，５－ナフチリジンまたはキノリン
CA3222549A1 (en) Combination therapy for cancer treatment
EP2476682B1 (en) 8-oxodihydropurine derivative
KR20220034038A (ko) Bcl-2 억제제의 나노입자 제형
WO2024020084A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
WO2020198067A1 (en) Pkm2 modulators and methods for their use
WO2019145719A1 (en) Inhibitors of ras-effector protein interactions
EA045493B1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150909

FZDE Discontinued

Effective date: 20170303